Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Medtronic PLC (MDT) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Medtronic PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Medtronic PLC trades at $90.61 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 3.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Medtronic PLC pays a 3.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYMDT
Market Cap
$29.60B$116.07B
Sector
HealthHealth
52-Week High
$491.22$105.35
52-Week Low
$205.48$73.75
Enterprise Value
$27.56B$134.82B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Medtronic PLC

Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.

The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT